Colorectal Carcinoma
|
0.510 |
Biomarker
|
disease |
BEFREE |
Our results implicate ABCB5 as a critical determinant of CRC invasiveness and suggest that ABCB5 blockade might represent a strategy in CRC therapy, even independently of ABCB5's function as an MDR mediator.
|
29789423 |
2018 |
Colorectal Carcinoma
|
0.510 |
Biomarker
|
disease |
CTD_human |
The role of ABC transporters in progression and clinical outcome of colorectal cancer.
|
22294766 |
2012 |
Colorectal Carcinoma
|
0.510 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies in four melanoma cell lines with various genetic backgrounds showed an increase in the proliferation and migration capacity of mutant ABCB5-expressing cells, suggesting that ABCB5 plays a role in the development of melanoma as a tumor suppressor gene.
|
30905807 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The transmembrane protein ABCB5 is closely linked to tumorigenicity, progression and disease recurrence of diverse human malignancies, including melanoma.
|
30941990 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ABCB5 transmembrane protein was tested due to its well-known role in the initiation, invasion and metastatic spread of various cancers, including melanoma.
|
28704989 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although neither of these two genes have been previously associated with sarcoma, ABCB5 has been shown to share clinical drug resistance associations with melanoma and leukaemia and C16orf96 shares regulatory elements with genes that are involved with TNF-alpha mediated apoptosis in a p53/TP53-dependent manner.
|
31053105 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Firstly, the expression of a subset of melanoma genes was investigated by RT-PCR in MCSP-enriched and ABCB5-enriched CTCs isolated from a total of 59 blood draws from 39 melanoma cases.
|
30769764 |
2019 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ATP binding cassette subfamily B member 5 (ABCB5) has been identified as a tumour-initiating cell marker and is expressed in various malignancies, including melanoma.
|
28940439 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to determine whether ABCB5 is highly expressed in BRAF inhibitor-resistant melanoma cells and to evaluate whether ABCB5 is involved in the development of resistance to BRAF inhibitors in cutaneous melanoma.
|
29929490 |
2018 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of ABCB5 expression reduces melanoma cell migration and invasion in vitro and melanoma pulmonary metastasis in tumor xenograft mice.
|
28821433 |
2017 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This is the first study showing the relationship between miR-340-5p and expression of ABCB5, a transmembrane transporter involved in drug resistance considered as a marker of melanoma stem-like cells.
|
26554847 |
2015 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Selected anti-clonogenic compounds might be further investigated as potential adjuvants targeting melanoma stem-like cells in the combined anti-melanoma therapy, whereas selected cytotoxic but not anti-clonogenic compounds, which increased the frequency of ABCB5-positive cells and remained slow-cycling cells unaffected, might be considered as a tool to enrich cultures with cells exhibiting melanoma stem cell characteristics.
|
24595456 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the helicase HAGE has a key role in the resistance of ABCB5+ MMICs to IFNα treatment and that cancer therapies targeting HAGE may have broad implications for the treatment of malignant melanoma.
|
24525737 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Flow cytometry and immunofluorescence analysis indicated that sphere-derived cells contained a smaller proportion of cells expressing the candidate surface markers of melanoma stem cells such as ABCB5, CD133, CD20 and CD271, and a larger proportion of cells expressing melanocytic differentiation markers such as HMB45 and S100 protein, compared with adherent cells.
|
23752306 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
At the molecular level, we show that melanoma Rh123(low) cells overexpress HIF1α, pluripotency factor OCT4, and the ABCB5 marker of melanoma stem cells and downregulate the expression of Cyclin D1 and CDK4.
|
23355370 |
2013 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results identify novel associations of the ABCB5 K115E polymorphism with human pigmentation phenotype and melanoma risk and point to potential functional roles of ABCB5 in melanomagenesis.
|
23770371 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings corroborate models in which CD133(+)/ABCB5(+) melanoma cells reside in a complex anastomosing microvascular niche that encompasses CD144(+) VM channels as well as authentic endothelial cell-lined blood vessels.
|
22865455 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a melanoma xenograft model (WM266-4), we observed in vivo that ABCB5-expressing cells are enriched after a temozolomide treatment that induces a significant tumor regression.
|
22675422 |
2012 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The dedifferentiated melanoma cells acquired features associated with CSCs such as multipotent differentiation capacity and expression of melanoma CSC markers such as ABCB5 and CD271.
|
22286766 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo, melanoma-specific shRNA-mediated knockdown of VEGFR-1 blocked the development of ABCB5(+) VM morphology and inhibited ABCB5(+) VM-associated production of the secreted melanoma mitogen laminin.
|
21212411 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, definitive markers for the purification and further characterization of melanoma-initiating cells remained elusive.Recently, Schatton et al. provided solid evidence that the doxorubicin-resistant ATP-binding cassette transporter ABCB5 marks primitive cells capable of recapitulating melanomas in xenotransplantation models.
|
18328422 |
2008 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In serial human-to-mouse xenotransplantation experiments, ABCB5+ melanoma cells possess greater tumorigenic capacity than ABCB5- bulk populations and re-establish clinical tumour heterogeneity.
|
18202660 |
2008 |
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Moreover, our findings show that ABCB5 is a novel molecular marker for a distinct subset of chemoresistant, stem cell phenotype-expressing tumor cells among melanoma bulk populations and indicate that these chemoresistant cells can be specifically targeted via ABCB5 to enhance cytotoxic efficacy.
|
15899824 |
2005 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We identified and cloned two novel mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ABC transporter ABCB 5 in human melanoma cells.
|
15760339 |
2005 |